The US buys an additional 600,000 doses of GSK-Vir coronavirus antibody therapy

Get real time updates directly on you device, subscribe now.

The British pharmaceutical company GSK and US partner Vir Biotechnology announced on Tuesday that the United States had agreed to buy an additional 600,000 doses of coronavirus sotrovimab antibody therapy for an undisclosed price.

The agreement is part of the US government’s efforts to strengthen its “arsenal” of treatments for the Omicron variant of the coronavirus.

The two pharmaceutical companies have announced that additional doses of antibody therapy will be delivered to the US government for distribution in the first quarter of 2022.

It is recalled that the US had signed a $ 1 billion deal with the two companies in November to supply an unspecified number of doses of GSK-Vir monoclonal antibody therapy.

Sotrovimab, which is given by infusion, belongs to the class of monoclonal antibodies. These are compounds that are developed in the laboratory and mimic the body’s natural defenses. Tests have shown that the treatment works in the treatment of the rapidly transmitted Omicron variant.

Including the latter agreement, the two companies have so far entered into an agreement to supply approximately 1.7 million doses of antibody therapy worldwide.


Source From: Capital

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.

buy kamagra buy kamagra online $255 payday loans online same day no denial payday loans direct lenders only